About Viatris Inc.

Viatris Inc., formed through the merger of Mylan and Pfizer's Upjohn division in 2020, has created one of the world's largest generic pharmaceutical companies with a mission to provide affordable access to medicines globally. The company has built comprehensive manufacturing and distribution capabilities worldwide. VTRS stock price reflects the company's global scale and focus on accessible healthcare solutions.

Led by CEO Scott Smith, Viatris has focused on integration synergies and operational excellence while building a sustainable platform for global pharmaceutical access. The management team has implemented strategic initiatives to optimize the combined portfolio and capture cost efficiencies. Leadership's commitment to improving global healthcare access has been important for positioning the company and driving VTRS stock price performance.

Viatris operates by developing, manufacturing, and distributing generic pharmaceuticals, branded medicines, and complex dosage forms to patients worldwide through established distribution networks and healthcare partnerships. The company serves both developed and emerging markets with essential medications. With growing global healthcare needs and increasing focus on healthcare affordability, continued demand for generic pharmaceuticals, and Viatris' established global platform and manufacturing capabilities, VTRS offers investors exposure to essential pharmaceuticals with significant scale advantages and potential for steady cash generation through providing accessible healthcare solutions worldwide.